Home> Products> improve insulin sensitivity and secretion

{ "products": [ { "_id": "68822dd35b399ba6097ed11b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET G 0.5 FORTE", "description": "SEIZMET G0.5 FORTE is a powerful oral antidiabetic medication formulated with a combination of glimepiride and metformin hydrochloride. This dual-action therapy is specifically designed for patients with type 2 diabetes mellitus who are unable to control their blood sugar levels with diet and exercise alone. The combination works in synergy to manage blood glucose effectively, reduce insulin resistance, and improve overall glycemic control.\n\nGlimepiride and metformin hydrochloride tablets are a combination medication used to treat type 2 diabetes. They work by helping the pancreas release more insulin and by reducing the amount of sugar produced by the liver, while also making the body more sensitive to insulin.\n\nWhat is SEIZMET G0.5 FORTE?\nSEIZMET G0.5 FORTE contains two active ingredients:\n\nGlimepiride (0.5 mg): A sulfonylurea class drug that stimulates the beta cells of the pancreas to release insulin.\n\nMetformin Hydrochloride: A biguanide that works primarily by suppressing hepatic glucose production and increasing insulin sensitivity in muscles.\n\nTogether, this combination addresses both insulin deficiency and resistance—two key factors in type 2 diabetes.\n\nUses of SEIZMET G0.5 FORTE:\n\nEffective in managing type 2 diabetes mellitus\n\nHelps in reducing fasting and postprandial blood glucose levels\n\nUsed as monotherapy or in combination with other antidiabetic agents\n\nReduces the risk of diabetic complications such as nephropathy, retinopathy, and cardiovascular disease\n\nSide Effects of SEIZMET G0.5 FORTE:\nLike all medications, glimepiride and metformin hydrochloride tablets may cause side effects in some patients. Common side effects include:\n\nNausea or vomiting\n\nDiarrhea\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness\n\nMetallic taste in the mouth\n\nAbdominal discomfort\n\nIn rare cases, it may cause lactic acidosis, a serious condition related to metformin accumulation.\n\nPrecautions Before Using SEIZMET G0.5 FORTE:\n\nAlways take the medication exactly as prescribed by your doctor.\n\nInform your physician if you have a history of liver or kidney disorders, heart disease, or alcohol abuse.\n\nAvoid excessive alcohol consumption while on this medication as it increases the risk of lactic acidosis.\n\nNot recommended for patients with type 1 diabetes or diabetic ketoacidosis.\n\nRegularly monitor your blood sugar and kidney function.\n\nThis medicine should be used during pregnancy only if absolutely necessary and under medical supervision.\n\nDrug Interactions: What Drugs Interact with SEIZMET G0.5 FORTE?\nCertain medications can interact with glimepiride and metformin, affecting their efficacy or increasing the risk of side effects. These include:\n\nBeta-blockers (e.g., propranolol) – may mask hypoglycemia symptoms\n\nDiuretics – may impair blood sugar control\n\nACE inhibitors – may increase the blood glucose-lowering effect\n\nCorticosteroids – may reduce the effectiveness of the medication\n\nAntipsychotics (e.g., olanzapine)\n\nAlcohol – increases the risk of lactic acidosis\n\nCimetidine – may raise metformin levels in the body\n\nAlways inform your healthcare provider about all medications, supplements, or herbal products you are taking.\n\nConclusion:\nSEIZMET G0.5 FORTE is a trusted, effective choice for managing type 2 diabetes, offering the combined benefits of glimepiride and metformin hydrochloride tablets. With dual mechanisms—enhancing insulin secretion and improving insulin sensitivity—it delivers comprehensive glycemic control. When taken as directed and with regular monitoring, SEIZMET G0.5 FORTE can be a valuable part of a diabetic patient’s treatment regimen, contributing to a healthier, more balanced life.\n\nFor best results, pair this medication with a proper diet, regular physical activity, and periodic blood glucose testing. Always consult your healthcare provider for personalized advice.", "price": 125.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2151, "imageuri": "https://productimages.withfloats.com/actual/68822dd8296c4d19d55e8535.png", "tileimageuri": "https://productimages.withfloats.com/tile/68822dd8296c4d19d55e8535.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-07-24T12:57:55.385Z", "updatedon": "2025-07-24T12:57:55.385Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-g-0-5-forte/2151", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "glimepiride and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "glimepiride and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "681c5e9e5a26e4010ea42029", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ST-GLIPTIN M 100/ 1000", "description": "ST-GLIPTIN M 100/1000 is an advanced oral antidiabetic medication designed for the effective management of Type 2 Diabetes Mellitus. This powerful combination of Sitagliptin (100 mg) and Metformin Hydrochloride (1000 mg) offers dual action in controlling elevated blood glucose levels, especially in patients who do not respond adequately to metformin or sitagliptin alone. It is intended for adults and is generally used in conjunction with diet and exercise to enhance glycemic control.\n\nKey Ingredients\nSitagliptin (100 mg)\nSitagliptin is a DPP-4 (Dipeptidyl Peptidase-4) inhibitor that increases the levels of incretin hormones, which help regulate blood sugar by increasing insulin release and decreasing glucagon levels.\n\nMetformin Hydrochloride (1000 mg)\nMetformin belongs to the biguanide class of antidiabetics. It works by reducing the amount of sugar produced by the liver and improves the body’s sensitivity to insulin, facilitating better glucose utilization.\n\nKey Benefits\nHelps reduce both fasting and postprandial (after-meal) blood glucose levels effectively\nImproves overall glycemic control in patients with Type 2 diabetes\nCombines two different mechanisms of action for better diabetes management\nMinimizes the risk of hypoglycemia compared to other antidiabetic therapies\nMay support weight neutrality or slight weight loss in diabetic individuals\n\nHow Does It Work?\nST-GLIPTIN M 100/1000 works through a synergistic mechanism by combining two effective antidiabetic agents:\n\nSitagliptin enhances the levels of incretin hormones, which help the pancreas produce more insulin and reduce the secretion of glucagon, especially when blood sugar is high.\nMetformin reduces hepatic glucose production and increases insulin sensitivity, which helps the body use glucose more efficiently.\nTogether, these agents provide comprehensive blood sugar control by addressing multiple physiological pathways involved in glucose metabolism.\n\nDirections for Use\nTake ST-GLIPTIN M 100/1000 exactly as prescribed by your physician.\nIt is typically taken once or twice daily with meals to reduce gastrointestinal side effects and optimize absorption.\nSwallow the tablet whole with water. Do not crush or chew the tablet.\nMaintain a balanced diet and follow an active lifestyle for best results.\nRegular blood sugar monitoring is essential to assess effectiveness and make any necessary dosage adjustments.\n\nSide Effects\nCommon side effects may include nausea, diarrhea, stomach upset, or headache.\nSome individuals may experience respiratory tract infections, sore throat, or a runny nose.\nLactic acidosis is a rare but serious side effect associated with high-dose metformin—seek immediate medical attention if symptoms like unusual fatigue, muscle pain, difficulty breathing, or abdominal discomfort occur.\nAllergic reactions such as rash, itching, or swelling are uncommon but possible.\nAlways inform your doctor of any persistent or bothersome side effects for timely intervention.", "price": 225.0, "discountamount": 68.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "1001000 works", "100 1000stgliptin", "work stgliptin", "balanced diet", "tablet maintain", "diabetic individuals", "sitagliptin 100 mg", "timely intervention", "rash itching", "medical attention", "highdose metforminseek", "assess effectiveness", "active lifestyle", "pancreas produce", "synergistic mechanism", "antidiabetic therapies", "hypoglycemia compared", "glycemic control", "biguanide class", "incretin hormones", "respond adequately", "powerful combination", "insulin facilitating", "sugar produced", "side effect", "bodys sensitivity", "effective management", "blood sugar", "increases insulin sensitivity", "regulate blood sugar", "glucose metabolism directions", "increasing insulin release", "bothersome side effects", "diabetes management minimizes", "optimize absorption swallow", "slight weight loss", "support weight neutrality" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2107, "imageuri": "https://productimages.withfloats.com/actual/681c5e9f5e6dd8f19a0309c3.png", "tileimageuri": "https://productimages.withfloats.com/tile/681c5e9f5e6dd8f19a0309c3.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-08T07:34:54.516Z", "updatedon": "2025-05-08T07:35:36.782Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/st-gliptin-m-100-1000/2107", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "sitagliptin and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin and Metformin hydrochloride tablets Uses in Hindi", "sitagliptin and metformin hydrochloride tablets 50/1000 uses in hindi", "sitagliptin and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67e1547f527b20030c4156f0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin 5 mg and Metformin Hydrochloride 500 mg", "description": "EMPATECH MET 5/500 is a powerful combination of Empagliflozin 5 mg and Metformin Hydrochloride 500 mg designed to effectively manage Type 2 Diabetes Mellitus. It helps control blood sugar levels, improves insulin sensitivity, and reduces the risk of diabetes-related complications. This dual-action formula works by limiting glucose absorption while enhancing the body's natural ability to utilize insulin, making it a preferred choice for diabetic patients seeking optimal glycemic control.\n \nKey Benefits:\nEffective Blood Sugar Control – Lowers HbA1c levels and maintains stable glucose levels.\nSupports Weight Management – Promotes calorie loss by eliminating excess glucose.\nReduces Cardiovascular Risk – Empagliflozin has heart-protective benefits, reducing the risk of heart-related complications.\nImproves Insulin Sensitivity – Helps the body use insulin more effectively.\nReduces the Risk of Hypoglycemia – Lowers blood sugar without excessive insulin spikes.\n\nHow Does It Work?\n\nEmpagliflozin blocks the SGLT2 (Sodium-Glucose Co-Transporter 2) in the kidneys, preventing glucose reabsorption and allowing excess sugar to be excreted through urine.\nMetformin decreases glucose production in the liver and enhances insulin sensitivity, helping the body use glucose more efficiently.\nTogether, they provide comprehensive diabetes management by regulating blood sugar without causing significant hypoglycemia.\n \nDirections for Use:\n \n\nTake EMPATECH MET 5/500 as prescribed by your doctor.\n\nSwallow the tablet whole with water, preferably with meals to minimize stomach discomfort.\n\nMaintain a balanced diet and regular exercise for optimal results.\n\nDo not stop or change the dosage without consulting your doctor.\n\n \nSide Effects:\n \n\nWhile EMPATECH MET 5/500 is generally well-tolerated, some individuals may experience:\n\nFrequent Urination – Due to glucose excretion in urine.\nMild Stomach Discomfort – Including nausea, bloating, or diarrhea.\nDizziness or Weakness – Especially in the initial stages of treatment.\nUrinary Tract Infections (UTIs) – A possible side effect of increased glucose in urine.\nLactic Acidosis (Rare but Serious) – Symptoms include muscle pain, breathing difficulty, or extreme tiredness; seek medical attention if these occur.", "price": 115.0, "discountamount": 35.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "effectively reduces", "increased glucose", "initial stages", "diarrhea dizziness", "nausea bloating", "glucose excretion", "generally welltolerated", "optimal results", "regular exercise", "balanced diet", "water preferably", "empatech met 5500", "preferred choice", "diabetesrelated complications", "powerful combination", "side effect", "doctor swallow", "empagliflozin 5mg", "doctor side effects", "limiting glucose absorption", "excessive insulin spikes", "utilize insulin making", "work empagliflozin blocks", "regulating blood sugar", "allowing excess sugar", "heartprotective benefits reducing", "bodys natural ability", "dualaction formula works" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2074, "imageuri": "https://productimages.withfloats.com/actual/67e15496bb48c9c5202ecea6.png", "tileimageuri": "https://productimages.withfloats.com/tile/67e15496bb48c9c5202ecea6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-03-24T12:47:59.972Z", "updatedon": "2025-03-27T12:53:02.808Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-5-mg-and-metformin-hydrochloride-500-mg/2074", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "EMPATECH MET 5/500", "category": "DIABETIC RANGE", "tags": [ "empagliflozin/metformin 5 mg/1000 mg", "empagliflozin 12.5 mg+metformin 500 mg price", "empagliflozin + metformin combination brand name" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "670cec40396e427ba56d673c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gliclazide IP (40 mg), Metformin Hydrochloride IP (500 mg), Voglibose IP (0.3 mg)", "description": "GLICLAGLAZE TRIO 40/0.3 is a prescription medication used for managing type 2 diabetes. It contains a combination of three active ingredients—Gliclazide IP (40 mg), Metformin Hydrochloride IP (500 mg), and Voglibose IP (0.3 mg)—each targeting different pathways to help control blood sugar levels.\n\n \nKey Benefits:\n \n\nProvides comprehensive blood sugar control for patients with type 2 diabetes.\nReduces fasting and post-meal glucose levels.\nLowers the risk of complications associated with high blood sugar, such as cardiovascular issues and neuropathy.\n \nHow Does It Work?\n \n\nGliclazide enhances insulin secretion from the pancreas.\nMetformin decreases glucose production in the liver and improves insulin sensitivity.\nVoglibose slows the breakdown of carbohydrates in the intestines, minimizing sudden spikes in blood sugar levels after meals.\n \nDirections for Use:\n \n\nTake this medication as directed by your healthcare provider, typically once or twice daily with meals.\nSwallow the tablet whole with water.\nDo not crush or chew the tablet.\nRegularly monitor your blood sugar levels as advised by your doctor.\n \nSide Effects:\n \n\nCommon: Nausea, diarrhea, stomach pain, and low blood sugar (hypoglycemia).\nLess Common: Headaches, dizziness, and mild gastrointestinal discomfort.\nRare but Severe: Severe hypoglycemia, lactic acidosis (with metformin), or allergic reactions.", "price": 205.0, "discountamount": 61.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "stomach pain", "Side Effects", "Key Benefits", "Voglibose IP", "sudden spikes", "Gliclazide IP", "lactic acidosis", "type 2 diabetes", "low blood sugar", "GLICLAGLAZE TRIO", "high blood sugar", "insulin secretion", "allergic reactions", "different pathways", "glucose production", "blood sugar levels", "Severe hypoglycemia", "healthcare provider", "insulin sensitivity", "cardiovascular issues", "prescription medication", "post-meal glucose levels", "three active ingredients", "Metformin Hydrochloride IP", "mild gastrointestinal discomfort", "comprehensive blood sugar control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1990, "imageuri": "https://productimages.withfloats.com/actual/670cec44d902143eb0bc8e8e.png", "tileimageuri": "https://productimages.withfloats.com/tile/670cec44d902143eb0bc8e8e.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-10-14T10:02:40.431Z", "updatedon": "2024-10-14T10:02:40.431Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclazide-ip-40-mg-metformin-hydrochloride-ip-500-mg-voglibose-ip-0-3-mg-/1990", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": " GLICLAGLAZE TRIO 40/0.3 ", "category": "DIABETIC RANGE", "tags": [ "Vildagliptin and voglibose combination", "Glimepiride, Metformin hydrochloride er Voglibose ", "Glimepiride 3mg Metformin (500mg Voglibose 0.3mg b" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662cd3e870e7b20c49e689e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD G3 M0.3 ", "description": "VOGLIGOLD G3 M0.3 \nVoglibose 0.3 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg\nIntroduction to VOGLIGOLD G3 M0.3\nVOGLIGOLD G3 M0.3 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains three active ingredients: Voglibose 0.3mg, Glimepiride 3mg, and Metformin Hydrochloride 500mg. This multi-action formula targets different aspects of glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVoglibose 0.3mg\nVoglibose is an alpha-glucosidase inhibitor that works by:\n\nSlowing Carbohydrate Absorption: Voglibose inhibits the alpha-glucosidase enzyme in the small intestine, delaying the breakdown of complex carbohydrates into glucose. This helps to smooth out postprandial (after-meal) blood glucose peaks.\nGlimepiride 3mg\nGlimepiride is a sulfonylurea that helps control blood sugar by:\n\nStimulating Insulin Secretion: Glimepiride stimulates the pancreas to release more insulin, which helps lower blood sugar levels, particularly after meals.\nMetformin Hydrochloride 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReducing Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproving Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreasing Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nBenefits of VOGLIGOLD G3 M0.3\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Voglibose, Glimepiride, and Metformin effectively manages both fasting and postprandial blood sugar levels.\nEnhanced Insulin Secretion and Sensitivity: Glimepiride enhances insulin secretion, while Metformin improves insulin sensitivity, and Voglibose slows carbohydrate absorption.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: The risk of hypoglycemia is minimized due to the complementary actions of the three components.\nWeight Neutrality: Metformin and Voglibose are generally weight neutral, making this combination favorable for patients concerned about weight gain associated with diabetes medications.\nHow to Use VOGLIGOLD G3 M0.3\nDosage and Administration\nRecommended Dosage: The typical dosage is one tablet taken once or twice daily, as prescribed by your healthcare provider.\nAdministration: Take the tablet with meals to reduce gastrointestinal side effects and enhance the absorption of Metformin. Swallow the tablet whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD G3 M0.3 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vogligold-g3-m0-3-134319", "price": 185.0, "discountamount": 55.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "meal", "diet", "Order", "glass", "water", "EMAIL", "liver", "adults", "amount", "Fasting", "readings", "patients", "pancreas", "Low Risk", "exercise", "breakdown", "same time", "biguanide", "Decreasing", "one tablet", "Guidelines", "Glimepiride", "Adjustments", "weight gain", "information", "utilization", "Optimal Use", "best results", "Introduction", "sterispharma", "sulfonylurea", "Hypoglycemia", "muscle cells", "sterisonline", "CALL/WHATSAPP", "Voglibose 0.3", "Administration", "typical dosage", "glucose uptake", "treatment plan", "Consistent Use", "Key Components", "small intestine", "glycemic control", "three components", "VOGLIGOLD G3 M0.3", "different aspects", "Weight Neutrality", "several mechanisms", "glucose regulation", "Regular monitoring", "Recommended Dosage", "blood glucose peaks", "Insulin Sensitivity", "healthcare provider", "diabetes medications", "effective management", "multi-action formula", "complex carbohydrates", "Intestinal Absorption", "complementary actions", "gastrointestinal tract", "combination medication", "Metformin Hydrochloride", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "three active ingredients", "type 2 diabetes mellitus", "Enhanced Insulin Secretion", "Additional Health Benefits", "Hepatic Glucose Production", "alpha-glucosidase inhibitor", "gastrointestinal side effects", "Postprandial Glucose Management", "postprandial blood sugar levels", "comprehensive blood sugar control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1519, "imageuri": "https://productimages.withfloats.com/actual/667d30b6c303c6d6ad136ea4.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d30b6c303c6d6ad136ea4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T09:05:02.904Z", "updatedon": "2024-06-27T09:28:16.215Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vogligold-g3-m0-3-/1519", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD G3 M0.3 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 3mg+metformin 500mg+voglibose 0.3 mg", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c4c88ecffe165c354dc1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE PIO ", "description": "VILDIABATE PIO \nVildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg\nIntroduction to VILDIABATE PIO\nVILDIABATE PIO is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains two active ingredients: Vildagliptin 50mg and Pioglitazone Hydrochloride 15mg. This dual-action formula targets different aspects of glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nPioglitazone Hydrochloride 15mg\nPioglitazone is a thiazolidinedione that improves insulin sensitivity in muscle and adipose (fat) tissues. It works by:\n\nIncreasing Insulin Sensitivity: Pioglitazone enhances the body's response to insulin, allowing for better glucose uptake and utilization by cells.\nReducing Hepatic Glucose Production: Pioglitazone decreases the amount of glucose produced by the liver, helping to lower fasting blood sugar levels.\nBenefits of VILDIABATE PIO\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Vildagliptin and Pioglitazone effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Vildagliptin enhances insulin secretion in response to meals, while Pioglitazone improves insulin sensitivity in peripheral tissues.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nCardioprotective Effects: Pioglitazone may provide additional cardiovascular benefits, such as improving lipid profiles and reducing inflammation, which can be beneficial for patients with diabetes who are at risk of cardiovascular diseases.\nWeight Management: While Pioglitazone may cause some weight gain due to fluid retention, Vildagliptin is generally weight neutral, balancing the overall effect on body weight.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage of VILDIABATE PIO is one tablet taken once daily, preferably with a meal to enhance absorption and reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE PIO regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-pio-134257\n", "price": 295.0, "discountamount": 88.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "meals", "EMAIL", "cells", "liver", "water", "glass", "GLP-1", "amount", "muscle", "adults", "Fasting", "adipose", "patients", "Low Risk", "exercise", "readings", "response", "Enhancing", "same time", "one tablet", "Mechanisms", "Increasing", "Guidelines", "absorption", "utilization", "Optimal Use", "information", "body weight", "Adjustments", "weight gain", "DPP-4 enzyme", "inflammation", "Introduction", "Vildagliptin", "Hypoglycemia", "sterispharma", "best results", "fat) tissues", "sterisonline", "CALL/WHATSAPP", "Administration", "VILDIABATE PIO", "glucose uptake", "Key Components", "Consistent Use", "treatment plan", "overall effect", "lipid profiles", "typical dosage", "Incretin Levels", "low blood sugar", "fluid retention", "glycemic control", "glucagon release", "DPP-4) inhibitor", "Weight Management", "insulin secretion", "incretin hormones", "different aspects", "thiazolidinedione", "peripheral tissues", "glucose regulation", "Regular monitoring", "healthcare provider", "dual-action formula", "insulin sensitivity", "blood glucose levels", "effective management", "dipeptidyl peptidase-4", "two active ingredients", "combination medication", "cardiovascular diseases", "Cardioprotective Effects", "type 2 diabetes mellitus", "meal) blood sugar levels", "glucose-dependent manner", "Recommended Dosage Dosage", "Pioglitazone Hydrochloride", "Additional Health Benefits", "Hepatic Glucose Production", "gastrointestinal side effects", "Postprandial Glucose Management", "comprehensive blood sugar control", "additional cardiovascular benefits", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1512, "imageuri": "https://productimages.withfloats.com/actual/667d3d8c5443982e2f655655.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3d8c5443982e2f655655.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:28:56.298Z", "updatedon": "2024-06-27T10:23:02.274Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vildiabate-pio-/1512", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE PIO ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin hydrochloride tablets uses", "vildagliptin + metformin + glimepiride combination", "vildagliptin 50 mg side effects", "vildagliptin and pioglitazone hydrochloride" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662b5587de2b5203089e01d", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 850 ", "description": "VILDIABATE M 850 \nMetformin (850mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 850\nVILDIABATE M 850 is a combination medication designed to manage type 2 diabetes mellitus effectively. It combines Metformin Hydrochloride Sustained Release (SR) 850mg and Vildagliptin 50mg. This dual-action formulation targets different pathways involved in glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 850mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained-release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 850\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight-neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once or twice daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 850 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-850-133455", "price": 299.0, "discountamount": 89.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "EMAIL", "water", "glass", "liver", "GLP-1", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "readings", "response", "Enhancing", "same time", "biguanide", "Guidelines", "one tablet", "weight gain", "Optimal Use", "information", "Adjustments", "utilization", "Vildagliptin", "Metformin SR", "sterispharma", "Hypoglycemia", "Introduction", "best results", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "treatment plan", "glucose uptake", "steady release", "typical dosage", "Key Components", "Administration", "Weight Neutral", "Consistent Use", "low blood sugar", "Incretin Levels", "gradual release", "glycemic control", "VILDIABATE M 850", "glucagon release", "Prolonged Effect", "DPP-4) inhibitor", "incretin hormones", "insulin secretion", "glucose regulation", "several mechanisms", "different pathways", "Regular monitoring", "healthcare provider", "Insulin Sensitivity", "blood glucose levels", "Intestinal Absorption", "combination medication", "dipeptidyl peptidase-4", "gastrointestinal tract", "dual-action formulation", "meal) blood sugar levels", "type 2 diabetes mellitus", "glucose-dependent manner", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "sustained-release (SR) formulation", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1504, "imageuri": "https://productimages.withfloats.com/actual/667d44a2576e8da931df856b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d44a2576e8da931df856b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T07:23:04.367Z", "updatedon": "2024-06-27T10:53:21.595Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-m-850-/1504", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 850 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin 50/850 price", "vildagliptin and metformin hydrochloride tablets s" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }